KFF November 4, 2024
Elizabeth Williams, Robin Rudowitz, Clea Bell

GLP-1 (glucagon-like peptide-1) drugs have been used as a treatment for type 2 diabetes for over a decade, but newer forms of these drugs have gained widespread attention for their effectiveness as a treatment for obesity. While these drugs have provided new opportunities for obesity treatment, they have also raised questions about access to and affordability of these drugs. These drugs are expensive when purchased out of pocket, and coverage in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, though a number of state Medicaid programs and other payers are re-evaluating their coverage policies. Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicaid, Pharma / Biotech
For people with opioid addiction, Medicaid 'unwinding' raises the stakes
Medicaid Aiming to Improve Patient Access to High-Cost Therapies
New Tribal Health Medicaid, CHIP Reimbursement Aims to Improve Indigenous Disparities
Medicaid and CHIP Eligibility Expansions and Coverage Changes for Children Since the Start of the Pandemic
Medicaid enrollment associated with higher risk of cancer death

Share This Article